

JOURNAL OF HEPATOLOGY

The Home of Liver Research

VOLUME 70, ISSUE 3, PAGES 335–582

FROM THE EDITOR'S DESK

From the Editor's desk...

R. Moreau, R. Bataller, T. Berg, S. Lotersztajn, J. Zucman-Rossi and R. Jalan 335

EDITORIALS

The EASL International Liver Foundation: A growing pup with missions that are distinct yet integrated with those of its mother

M. Colombo and T.H. Karlsen 339

HCMV jogs the 'memory' of NK cells in HBV

U.S. Gill and L. Golden-Mason 343

Fa(s)t assessment of the liver graft: Is it relevant?

P. Nahon and O. Soubrane 346

NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter

J.H. Tabibian and K.D. Lindor 348

RESEARCH ARTICLES

Viral Hepatitis

NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection

A. Schuch, B.F. Zecher, P.A. Müller, M.P. Correia, F. Daul, C. Rennert, C. Tauber, K. Schlitt, T. Boettler, C. Neumann-Haefelin, H. Hengel, H. Pircher, A. Cerwenka, R. Thimme and M. Hofmann 351

HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues

T.C.-F. Yip, G.L.-H. Wong, H.L.-Y. Chan, Y.-K. Tse, K.L.-Y. Lam, G.C.-Y. Lui and V.W.-S. Wong 361

Epidemiology and natural history of hepatitis C virus infection among children and young people

L. Modin, A. Arshad, B. Wilkes, J. Benselin, C. Lloyd, W.L. Irving and D.A. Kelly 371

Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C

R. D'Ambrosio, L. Pasulo, M. Puoti, M. Vinci, M. Schiavini, S. Lazzaroni, A. Soria, F. Gatti, B. Menzaghi, A. Aghemo, F. Capelli, M.G. Rumi, L. Morini, A. Giorgini, M.G. Pigozzi, A. Rossini, F. Maggiolo, A. Pan, M. Memoli, O. Spinelli, P. Del Poggio, V. Saladino, A. Spinetti, A. De Bona, A. Capretti, C. Uberti-Foppa, P. Bonfanti, N. Terreni, F. Menozzi, A.E. Colombo, O. Giglio, R. Centenaro, M. Borghi, C. Baiguera, V. Picciotto, S. Landonio, A. Gori, C. Magnani, F. Noventa, S. Paolucci, P. Lampertico, S. Fagioli and on behalf of the NAVIGATORE-Lombardia Study Group 379

HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape

L.V. Pham, S.B. Jensen, U. Fahnøe, M.S. Pedersen, Q. Tang, L. Ghanem, S. Ramirez, D. Humes, S.B.N. Serre, K. Schønning, J. Bukh and J.M. Gottwein 388

Cirrhosis

Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe

J. Fernández, V. Prado, J. Trebicka, A. Amoros, T. Gustot, R. Wiest, C. Deulofeu, E. Garcia, J. Acevedo, V. Fuhrmann, F. Durand, C. Sánchez, M. Papp, P. Caraceni, V. Vargas, R. Bañares, S. Piano, M. Janicko, A. Albillos, C. Alessandria, G. Soriano, T.M. Welzel, W. Laleman, A. Gerbes, A. De Gottardi, M. Merli, M. Coenraad, F. Saliba, M. Pavesi, R. Jalan, P. Ginès, P. Angeli, V. Arroyo and the European Foundation for the Study of Chronic Liver Failure (EF-Clif) 398

Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices

H.Y. Kim, Y.H. So, W. Kim, D.-W. Ahn, Y.J. Jung, H. Woo, D. Kim, M.Y. Kim and S.K. Baik 412

Transplantation

Evaluation of a micro-spectrometer for the real-time assessment of liver graft with mild-to-moderate macrosteatosis: A proof of concept study

N. Gölse, C. Cosse, M.-A. Allard, A. Laurenzi, M. Tedeschi, N. Guglielmo, E. Fernandez-Sevilla, M. Robert, B. Tréchet, D. Pietrasz, G. Pittau, O. Ciacio, A. Sa Cunha, D. Castaing, D. Cherqui, R. Adam, D. Samuel, M. Sebah and E. Vibert 423

Liver Failure and Growth

Liver transplantation in patients with liver failure related to exertional heatstroke

P. Ichai, A. Laurent-Bellue, C. Camus, D. Moreau, M. Boutonnet, F. Saliba, J.M. Peron, C. Ichai, E. Gregoire, L. Aigle, J. Cousty, A. Quinart, B. Pons, M. Boudon, S. André, A. Coilly, T. Antonini, C. Guettier and D. Samuel 431

Cancer

Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection

G. Marasco, A. Colecchia, A. Colli, F. Ravaioli, G. Casazza, M.L. Bacchi Reggiani, A. Cucchetti, M. Cescon and D. Festi 440

Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma

S.J. Yu, C. Ma, B. Heinrich, Z.J. Brown, M. Sandhu, Q. Zhang, Q. Fu, D. Agdashian, U. Rosato, F. Korangy and T.F. Greten 449

Molecular and Cell Biology

Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury

M. Ruart, L. Chavarria, G. Campreciós, N. Suárez-Herrera, C. Montironi, S. Guixé-Muntet, J. Bosch, S.L. Friedman, J.C. Garcia-Pagán and V. Hernández-Gea 458

Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis

Y. Fan, S.K. Bazai, F. Daian, M. Arechederra, S. Richelme, N.A. Temiz, A. Yim, B.H. Habermann, R. Dono, D.A. Largaespada and F. Maina 470

Cholestasis and Autoimmune Diseases

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial

G.M. Hirschfield, O. Chazouillères, J.P. Drenth, D. Thorburn, S.A. Harrison, C.S. Landis, M.J. Mayo, A.J. Muir, J.F. Trotter, D.J. Leeming, M.A. Karsdal, M.J. Jaros, L. Ling, K.H. Kim, S.J. Rossi, R.M. Somaratne, A.M. DePaoli and U. Beuers 483

Genetic and Metabolic Diseases

A polymorphism in the Irisin-encoding gene (*FNDC5*) associates with hepatic steatosis by differential miRNA binding to the 3'UTR

M. Metwally, A. Bayoumi, M. Romero-Gomez, K. Thabet, M. John, L.A. Adams, X. Huo, R. Aller, C. García-Monzón, M. Teresa Arias-Loste, E. Bugianesi, L. Miele, R. Gallego-Durán, J. Fischer, T. Berg, C. Liddle, L. Qiao, J. George and M. Eslam 494

REVIEWS

Evolutionary biology of human hepatitis viruses

A. Rasche, A.-L. Sander, V.M. Corman and J.F. Drexler 501

Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study

M. Thursz, P.S. Kamath, P. Mathurin, G. Szabo and V.H. Shah 521

SPECIAL SECTIONS

PUBLIC HEALTH

Non-alcoholic fatty liver disease – A global public health perspective

Z.M. Younossi 531

Hepatology Snapshot

Different techniques for ultrasound liver elastography

L. Mulazzani, V. Cantisani and F. Piscaglia 545

LETTERS TO THE EDITOR

Type of organ failure and acute insult have important bearings in outcomes of liver transplantation: A pragmatic discourse

A. Roy and S. Taneja 548

Reply to: "Type of organ failure and acute insult have important bearings in outcomes of liver transplantation: A pragmatic discourse"

P.J. Thuluvath, A.J. Thuluvath, S. Hanish and Y. Savva 549

Only in the darkness can you see the stars: Severe alcoholic hepatitis and higher grades of acute-on-chronic liver failure

C.A. Phillips, P. Augustine, G. Padsalgi, R. Ahamed, A. Jose and S. Rajesh 550

Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring

M. van Seyen, E.J. Smolders, P. van Wijngaarden, J.P.H. Drenth, M. Wouthuyzen-Bakker, R.J. de Kneegt, P. Honkoop, O. El-Sherif, A. Colbers, D.J. Back and D.M. Burger 552

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

A. Boerekamps, T. Vanwolleghem, M. van der Valk, G.E. van den Berk, M. van Kasteren, D. Posthouwer, A.S.M. Dofferhoff, B. van Hoek, D. Ramsoekh, J. Koopsen, J. Schinkel, E. Florence, J.E. Arends and B.J. Rijnders 554

Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition

Y. Liu, W. Zeng, J. Xi, H. Liu, H. Liao, G. Yu, X. Chen and F. Lu 557

Reply to: "Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition"

G.P. Caviglia, A. Olivero and A. Smedile 559

Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018

L.M. Stamm, D.M. Brainard and J.G. McHutchison 561

Reply to: "Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL recommendations on treatment of Hepatitis C 2018"

European Association for the Study of the Liver 562

Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?

M. Riveiro-Barciela, E. Muñoz-Couselo, J. Fernandez-Sojo, N. Diaz-Mejia, R. Parra-López and M. Buti 564

Reply to: “Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?”

E. De Martin, J.-M. Michot, B. Papouin, S. Champiat, O. Lambotte, C. Robert, A. Marabelle, C. Guettier and D. Samuel 566

Predicting early hepatocellular carcinoma recurrence after resection: A comment for moving forward

X.-Y. Zhang, J. Ou, J.-Y. Chen and W.-W. Li 567

Toward the universal scoring system in treatment for patients with hepatocellular carcinoma

J. Kusakabe, D.J. Firl and K. Sasaki 568

Time to recurrence, but not recurrence-free survival, should be the endpoint used to predict early recurrence after HCC resection

W.-T. Yan, B. Quan, H. Xing, M.-C. Wu and T. Yang 570

Factors predicting early recurrence after surgical resection of hepatocellular carcinoma

Y.-M. Zhang, Z.-T. Zhou and G.-M. Liu 571

Reply to: Correspondence concerning “Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection”

A.W.H. Chan, S. Berhane, A. Cucchetti and P.J. Johnson 573

Treatment for solitary hepatocellular carcinoma ranging from 2 and 5 cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?

Y. Zhang, Y. Pei, X. Chen and W. Zhang 575

Reply to: “Treatment for solitary hepatocellular carcinoma ranging from 2 and 5 cm: Is the curative effect of no-touch multibipolar radiofrequency ablation comparable to that of surgical resection?”

K. Mohkam and J.-Y. Mabrut 576

CORRIGENDA

Corrigendum to “Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1” [J Hepatol 69 (2018) 1110–1122]

J.-J. Qin, W. Mao, X. Wang, P. Sun, D. Cheng, S. Tian, X.-Y. Zhu, L. Yang, Z. Huang and H. Li 578

Corrigendum to “Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B” [J Hepatol 69 (2018) 278–285]

Y.-C. Hsu, T.C.-F. Yip, H.J. Ho, V.W.-S. Wong, Y.-T. Huang, H.B. El-Serag, T.-Y. Lee, M.-S. Wu, J.-T. Lin, G.L.-H. Wong and C.-Y. Wu 581

Corrigendum to “Impaired brain glymphatic flow in experimental hepatic encephalopathy” [J Hepatol 69 (2019) 40–49]

A. Hadjihambi, I.F. Harrison, M. Costas-Rodríguez, F. Vanhaecke, N. Arias, R. Gallego-Durán, S. Mastitskaya, P.S. Hosford, S.W.M. Olde Damink, N. Davies, A. Habtesion, M.F. Lythgoe, A.V. Gourine and R. Jalan 582

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover image: Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe, by J. Fernández et al. on pp. 398–411 in this issue.

Cover design: Multiple pills bouncing off the surface of a bacteria. A depiction of drug resistance. By Caitlin Monney.